People living with multidrug-resistant (MDR) HIV-1 need options

it's time for RUKOBIA 

A first-in-class attachment inhibitor that directly targets HIV-1
to protect  CD4+ T-cells 1,2*

People living with multidrug-
resistant (MDR) HIV-1 need
options

it's time for RUKOBIA 

A first-in-class attachment
inhibitor that directly targets
HIV-1 to protect CD4+ T-cells 1,2*

INDICATION
RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.



*Prevents HIV-1 from interacting with host immune cells by binding gp120, leaving CD4+ T-cells untouched.

HIV-1=human immunodeficiency virus type-1;  gp120=glycoprotein 120.

Sign Up for our next webinar

Read more »
edge of yesterday sub hero image
edge of yesterday sub hero image

Listen to Edge of Yesterday:

A Podcast Series by ViiV Healthcare

Read more »

"My name is James. I’m a heavily treatment-experienced person living with HIV. I have a great deal of hopefulness. I just have to remain positive.”

James, living with HIV.

Compensated by ViiV Healthcare.

DISCOVER RUKOBIA

BRIGHTE CLINICAL
TRIAL

Learn about the efficacy and safety of RUKOBIA in BRIGHTE

Read more »
pill icon

DOSING AND DRUG
INTERACTIONS

Learn about administering RUKOBIA

Read more »

ViiV MEDICAL
INFORMATION

View our medical information library if you have a question about RUKOBIA

Read more »

A DEEPER LOOK AT RUKOBIA

RISKS & SIDE EFFECTS

Get information about the possible risks and side effects, including warnings and precautions and rates of discontinuation

Read more »
MOA

A NOVEL
MECHANISM
OF ACTION

Learn what makes RUKOBIA a first-in-class HIV-1 attachment inhibitor1,2

Read more »

EDUCATIONAL RESOURCES

View educational library for RUKOBIA, including videos and a downloadable resource

Read more »

References:

  1. Ackerman P, Thompson M, Molina J M, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
  2. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prod rug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):7 40-751.

FSTWCNT220002